Whitley W. Aamodt

Whitley W. Aamodt

Auto-generated profile, based on publicly available information

Whitley W. Aamodt

Department of Neurology, University of Pennsylvania, Philadelphia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2021 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
WAWhitley W. Aamodt
Whitley W. Aamodt
TWTeresa Waligorska
Teresa Waligorska
JSJunchao Shen
Junchao Shen
TTThomas Tropea
Thomas Tropea
ASAndrew Siderowf
Andrew Siderowf
ACAlice S. Chen‐Plotkin
Alice S. Chen‐Plotkin

8 August 2023 in Journal of Geriatric Psychiatry and Neurology
Verified
Journal Article
Open access
WAWhitley W. Aamodt
Whitley W. Aamodt
BKBenzi M. Kluger
Benzi M. Kluger
MMMiray Mirham
Miray Mirham
AJAnna Job
Anna Job
SLSamantha E. Lettenberger
Samantha E. Lettenberger
SSSandhya Seshadri
Sandhya Seshadri
Caregiver burden is a term that refers to the adverse effect of caregiving on the physical, emotional, social, spiritual, and financial well-being of the caregiver. Caregiver burden is associated with providing care to an individual with a chronic illness or disability, and the unique symptoms of Parkinson disease (PD) can amplify a patient’s needs and reliance on others, leading to adverse outcomes for patients and their caregivers. In this scoping review of the literature from January 2017 through April 2022 that included 114 studies, we provide an updated, evidence-based summary of patient and caregiver-related factors that contribute to caregiver burden in PD. We also describe the impact of caregiver stress and burden on caregivers based on qualitative research studies and review recent interventions to mitigate burden. By providing clinical updates for practitioners, this review is designed to improve recognition of caregiver burden in the post-pandemic era and foster the development of targeted interventions to reduce caregiver burden in PD.

1 April 2023 in Neurology Clinical Practice
Verified
Journal Article
Open access
PDF file
WAWhitley W. Aamodt
Whitley W. Aamodt
AWAllison W. Willis
Allison W. Willis
NDNabila Dahodwala
Nabila Dahodwala
Health disparities are pervasive in the United States. In the field of Parkinson disease (PD), profound racial and ethnic disparities exist in diagnosis, treatment, and research participation, leading to differential health outcomes and lack of generalizable research data. Racial and ethnic disparities not only limit our understanding of this complex heterogeneous disorder but also hamper our ability to provide new evidence-based care for America9s most vulnerable populations. In this report, we summarize findings from our comprehensive white paper for the Michael J. Fox Foundation that reviews the current state of knowledge on racial and ethnic disparities in PD care in the following areas: epidemiology, etiology, phenotype and diagnosis, treatment, and research. We also identify knowledge gaps and necessary policy changes to ensure equitable, high-value care for all persons with PD. These strategies are designed to help identify and reduce health disparities among persons with PD and may serve as a model for other neurologic diseases.

12 November 2024 in Neurology
Verified
Journal Article
Closed access
WAWhitley W. Aamodt
Whitley W. Aamodt
CSChuxuan Sun
Chuxuan Sun
NDNabila Dahodwala
Nabila Dahodwala
HEHolly Elser
Holly Elser
ASAndrea L.C. Schneider
Andrea L.C. Schneider
AWAllison W. Willis
Allison W. Willis
Although neurodegenerative diseases are a leading cause of death, little is known about health care utilization and cost during the end-of-life (EoL) period or how it compares with that of other life-limiting conditions. We aimed to describe and compare resource utilization among US Medicare decedents with neurodegenerative diseases with decedents with cancer. We conducted a retrospective study of Medicare Part A and B beneficiaries with Alzheimer disease (AD), Parkinson disease (PD), or amyotrophic lateral sclerosis (ALS) who died in 2018. Decedents diagnosed with malignant brain tumors or pancreatic cancer served as non-neurodegenerative comparators. Descriptive analyses examined demographic and clinical characteristics in the last year of life. The probabilities and associated costs of emergency department (ED), inpatient, skilled nursing facility (SNF), and hospice utilization during the last 12 and 6 months of life were also compared between persons with neurodegenerative diseases and cancer, adjusting for sociodemographic factors and comorbidity burden. A total of 1,126,799 Medicare beneficiaries died in 2018, of which 357,926 had a qualifying diagnosis. Persons with neurodegenerative diseases were older and more frequently received Medicaid assistance than persons with brain or pancreatic cancer. In all groups, health care service utilization increased over the last year of life, and total costs were predominantly attributable to inpatient care. In the last 6 months of life, neurologist care was infrequent among patients with neurodegenerative disease (AD: 1.5%; PD: 8.6%; ALS: 32.0%). Persons with neurodegenerative diseases as compared to persons with malignant brain tumors also had greater odds of ED use (AD: adjusted odds ratio [aOR] 1.17, 95% CI 1.11-1.23; PD: aOR 1.18, 95% CI 1.11-1.25; ALS: aOR 1.11, 95% CI 1.01-1.23), lower odds of hospitalization (AD: aOR 0.64, 95% CI 0.60-0.68; PD: aOR 0.65, 95% CI 0.61-0.69; ALS: aOR 0.33, 95% CI 0.30-0.37), and lower odds of hospice enrollment (AD: aOR 0.33, 95% CI 0.31-0.36; PD: aOR 0.33, 95% CI 0.31-0.36; ALS: aOR 0.41, 95% CI 0.36-0.46). The findings were similar in pancreatic cancer. Persons with neurodegenerative diseases in the United States are more likely to visit the ED and less likely to use inpatient and hospice services at EoL than persons with brain or pancreatic cancer. These group differences may stem from prognostic uncertainty and reflect inadequate EoL care practices, requiring further investigation to ensure more timely palliative care and hospice referrals.

21 October 2024 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
SSSabine Schneider
Sabine Schneider
WAWhitley W. Aamodt
Whitley W. Aamodt
APAmy A. Pruitt
Amy A. Pruitt
JBJoseph R. Berger
Joseph R. Berger

1 August 2023 in Neurology Clinical Practice
Verified
Journal Article
Closed access
PDF file
WAWhitley W. Aamodt
Whitley W. Aamodt
WBWarren B. Bilker
Warren B. Bilker
AWAllison W. Willis
Allison W. Willis
JFJohn T. Farrar
John T. Farrar
Background and Objective Current studies of end-of-life care in Parkinson disease (PD) do not focus on diverse patient samples or provide national views of end-of-life resource utilization. We determined sociodemographic and geographic differences in end-of-life inpatient care intensity among persons with PD in the United States (US). Methods This retrospective cohort study included Medicare Part A and Part B beneficiaries 65 years and older with a qualifying PD diagnosis who died between January 1, 2017, and December 31, 2017. Medicare Advantage beneficiaries and those with atypical or secondary parkinsonism were excluded. Primary outcomes included rates of hospitalization, intensive care unit (ICU) admission, in-hospital death, and hospice discharge in the last 6 months of life. Descriptive analyses and multivariable logistic regression models compared differences in end-of-life resource utilization and treatment intensity. Adjusted models included demographic and geographic variables, Charlson Comorbidity Index score, and Social Deprivation Index score. The national distribution of primary outcomes was mapped and compared by hospital referral region using Moran I. Results Of 400,791 Medicare beneficiaries with PD in 2017, 53,279 (13.3%) died. Of decedents, 33,107 (62.1%) were hospitalized in the last 6 months of life. In covariate-adjusted regression models using White male decedents as the reference category, odds of hospitalization was greater for Asian (AOR 1.38; CI 1.11–1.71) and Black (AOR 1.23; CI 1.08–1.39) male decedents and lower for White female decedents (AOR 0.80; CI 0.76–0.83). ICU admissions were less likely in female decedents and more likely in Asian, Black, and Hispanic decedents. Odds of in-hospital death was greater among Asian (AOR 2.49, CI 2.10–2.96), Black (AOR 1.11, CI 1.00–1.24), Hispanic (AOR 1.59; CI 1.33–1.91), and Native American (AOR 1.49; CI 1.05–2.10) decedents. Asian and Hispanic male decedents were less likely to be discharged to hospice. In geographical analyses, rural-dwelling decedents had lower odds of ICU admission (AOR 0.77; CI 0.73–0.81) and hospice discharge (AOR 0.69; CI 0.65–0.73) than urban-dwelling decedents. Nonrandom clusters of primary outcomes were observed across the US, with highest rates of hospitalization in the South and Midwest (Moran I = 0.134; p < 0.001). Discussion Most persons with PD in the US are hospitalized in the last 6 months of life, and treatment intensity varies by sex, race, ethnicity, and geographic location. These group differences emphasize the importance of exploring end-of-life care preferences, service availability, and care quality among diverse populations with PD and may inform new approaches to advance care planning.